Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00109928 · ClinicalTrials.gov registry record · Phase 2
S0350 Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Peripheral T-Cell Non-Hodgkin's Lymphoma
A Phase 2 study of Lymphoma, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
- 20
- Study locations
NCT00109928 is a Phase 2 study of Lymphoma that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 34 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 6 states.
The verdict
NCT00109928, a Phase 2 study of Lymphoma, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy, such as cisplatin, etoposide, gemcitabine, and methylprednisolone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. PURPOSE: This phase II trial is studying how well combination chemotherapy works in treating patients with newly diagnosed stage II, stage III, or stage IV T-cell non-Hodgkin's lymphoma.
Conditions Studied
Interventions
- DRUG cisplatin
- DRUG methylprednisolone
- DRUG gemcitabine
- DRUG etoposide
Study Locations (20)
California
- Kaiser Permanente - Fremont - Fremont
- Kaiser Permanente Medical Center - Hayward - Hayward
- Kaiser Permanente Medical Center - Oakland - Oakland
- South Sacramento Kaiser-Permanente Medical Center - Sacramento
- Kaiser Permanente Medical Center - San Francisco Geary Campus - San Francisco
- Kaiser Permanente Medical Center - Santa Teresa - San Jose
- Kaiser Foundation Hospital - San Rafael - San Rafael
- Kaiser Permanente Medical Center - Santa Clara Kiely Campus - Santa Clara
- Kaiser Permanente Medical Center - Santa Rosa - Santa Rosa
- Kaiser Permanente Medical Center - South San Francisco - South San Francisco
- Kaiser Permanente Medical Facility - Stockton - Stockton
- Kaiser Permanente Medical Center - Vallejo - Vallejo
- Kaiser Permanente Medical Center - Walnut Creek - Walnut Creek
Illinois
- Decatur Memorial Hospital Cancer Care Institute - Decatur
- Cardinal Bernardin Cancer Center at Loyola University Medical Center - Maywood
- Regional Cancer Center at Memorial Medical Center - Springfield
Arizona
- Arizona Cancer Center at University of Arizona Health Sciences Center - Tucson
Arkansas
- Arkansas Cancer Research Center at University of Arkansas for Medical Sciences - Little Rock
Connecticut
- Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center - Hartford
Florida
- M.D. Anderson Cancer Center at Orlando - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2005-09 |
| Est. Completion | 2014-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00109928
The ClinicalTrials.gov registry entry for NCT00109928 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (93% lower). The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lymphoma appearing as the primary indexed condition, and to 4 interventions - of which cisplatin is the first listed.
NCT00109928 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Illinois, Arizona.
Frequently Asked Questions
What is clinical trial NCT00109928 about?
NCT00109928 is a clinical study titled "S0350 Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Peripheral T-Cell Non-Hodgkin's Lymphoma". RATIONALE: Drugs used in chemotherapy, such as cisplatin, etoposide, gemcitabine, and methylprednisolone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cance...
What is the current status of trial NCT00109928?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2005-09. Estimated completion is 2014-04.
What conditions does trial NCT00109928 study?
This clinical trial studies the following conditions: Lymphoma.
What interventions are being tested in trial NCT00109928?
The interventions under investigation include: cisplatin (DRUG), methylprednisolone (DRUG), gemcitabine (DRUG), etoposide (DRUG).
Who is sponsoring clinical trial NCT00109928?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00109928 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.